Table 2.
Results of the primary antineoplastic activity of the investigated derivatives
| Cancer cell line | Derivative symbol | ||||
|---|---|---|---|---|---|
| 5-FU | RN | GN | RNs | GNs | |
| HeLa | 13.11±0.80 | 20.18±1.00 | 25.11±0.90 | 57.63±1.10 | 55.54±1.05 |
| SK-OV-3 | 22.16±1.05 | 29.58±0.90 | 31.58±1.00 | 62.91±0.95 | 73.36±0.95 |
| AR42J | 19.86±0.95 | 28.09±1.10 | 30.32±1.15 | 44.67±0.80 | 62.48±0.95 |
| MCF-7 | 12.46±1.10 | 22.81±1.10 | 24.17±0.85 | 47.82±1.20 | 54.56±0.90 |
| AB12 | 18.93±1.25 | 28.90±1.35 | 28.69±0.80 | 61.94±1.05 | 59.18±1.00 |
| KYSE-30 | 29.38±1.05 | 40.12±1.05 | 33.88±0.95 | 60.87±1.45 | 67.55±1.15 |
| LC540 | 23.67±0.85 | 52.47±1.10 | 47.17±1.05 | 83.04±1.20 | 76.48±1.05 |
| AMN3 | 24.64±1.20 | 37.63±1.10 | 42.11±1.15 | 49.37±1.00 | 59.32±1.05 |
The outcomes are represented as IC50±SD. The IC50 value was computed in μM, while the standard deviation (SD) was calculated for three separate experiments.